ABX-002

Autobahn Therapeutics has begun a Phase 2 clinical trial of ABX-002 as an adjunctive treatment for bipolar depression, aiming for biological and clinical proof-of-concept.

Autobahn Therapeutics received FDA clearance for its IND application for ABX-002, an adjunctive treatment for bipolar depression.

Multiple companies are developing novel therapies for Adrenoleukodystrophy (ALD), a rare genetic disorder affecting the adrenal glands and nervous system.

Autobahn Therapeutics has commenced the AMPLIFY Phase 2 trial to evaluate ABX-002 as an adjunctive treatment for major depressive disorder (MDD).

Third Arc Bio, led by former Johnson & Johnson executives, has raised $165 million in Series A funding to develop multifunctional antibodies for T-cell engagement in solid tumors and inflammatory conditions.